ARTICLE | Company News
MultiCell Technologies Inc, Oxis deal
March 30, 2015 7:00 AM UTC
Oxis and MultiCell’s MultiCell Immunotherapeutics Inc. subsidiary partnered to develop antibody-drug conjugates (ADCs) using Oxis’ OXS-2175 for triple-negative breast cancer (TNBC) and OXS-4235 for ...